[go: up one dir, main page]

ES2429422R1 - Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH - Google Patents

Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH Download PDF

Info

Publication number
ES2429422R1
ES2429422R1 ES201390019A ES201390019A ES2429422R1 ES 2429422 R1 ES2429422 R1 ES 2429422R1 ES 201390019 A ES201390019 A ES 201390019A ES 201390019 A ES201390019 A ES 201390019A ES 2429422 R1 ES2429422 R1 ES 2429422R1
Authority
ES
Spain
Prior art keywords
prevention
prepare
treatment
pharmaceutical composition
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201390019A
Other languages
English (en)
Other versions
ES2429422A2 (es
Inventor
Oleg Iliich Epshtein
Sergey Alexandrovich Tarasov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2429422(R1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2429422A2 publication Critical patent/ES2429422A2/es
Publication of ES2429422R1 publication Critical patent/ES2429422R1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH. La presente invención se refiere a una composición farmacéutica que comprende una forma activada-potenciada de un anticuerpo contra una proteína del VIH, y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH, incluido el SIDA.
ES201390019A 2010-08-06 2011-07-15 Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH Pending ES2429422R1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010133048/15A RU2535034C2 (ru) 2010-08-06 2010-08-06 Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2010133048 2010-08-06
PCT/IB2011/002369 WO2012017323A2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv

Publications (2)

Publication Number Publication Date
ES2429422A2 ES2429422A2 (es) 2013-11-14
ES2429422R1 true ES2429422R1 (es) 2014-11-12

Family

ID=44906248

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201390019A Pending ES2429422R1 (es) 2010-08-06 2011-07-15 Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
ES201430954A Pending ES2524385R1 (es) 2010-08-06 2011-07-15 Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES201430954A Pending ES2524385R1 (es) 2010-08-06 2011-07-15 Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH

Country Status (8)

Country Link
US (1) US20120294899A1 (es)
DE (1) DE112011102638T5 (es)
EA (1) EA201300132A1 (es)
ES (2) ES2429422R1 (es)
GB (1) GB2497453B8 (es)
RU (1) RU2535034C2 (es)
UA (1) UA112842C2 (es)
WO (1) WO2012017323A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EA030566B1 (ru) 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
GB2496337A (en) 2010-07-15 2013-05-08 Oleg Lliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
TWI728239B (zh) 2013-03-26 2021-05-21 美商環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
DE102020007979A1 (de) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055518A1 (fr) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Procede de traitement d'etats immuno-pathologiques et medicament correspondant
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
US20050123973A1 (en) * 2002-02-08 2005-06-09 Shaobing Hua Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation
FR2882557A1 (fr) * 2005-02-25 2006-09-01 Centre Nat Rech Scient Epitopes de vih et composition pharmaceutique les contenant
CN101287763A (zh) * 2005-08-15 2008-10-15 阿拉纳治疗有限公司 具有新世界灵长类区域的嵌合抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
WO2003055518A1 (fr) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Procede de traitement d'etats immuno-pathologiques et medicament correspondant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Barto¿ová V. et al. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Research. 2008, Vol. 78, páginas 275¿277 (todo el documento) *
Jonas W. B. et al. A critical overview of homeopathy. Ann. Intern. Med. 2003, Vol. 138, páginas 393-399 (todo el documento) *
Rezacova P. et al. Inhibition of HIV protease by monoclonal antibodies. J. Mol. Recognit. 2002, Vol. 15, páginas 272¿276 (todo el documento) *
Shang A. et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. The Lancet. 27.08.2005, Vol. 366, páginas 726-732 (todo el documento) *
Vickers A. J. et al. Clinical Trials of Homeopathy and Placebo: Analysis of a Scientific Debate. The Journal of Alternative and Complementary Medicine. 2000, Vol. 6, Nº 1, páginas 49-56 (todo el documento) *

Also Published As

Publication number Publication date
ES2524385A2 (es) 2014-12-05
GB201303868D0 (en) 2013-04-17
ES2429422A2 (es) 2013-11-14
ES2524385R1 (es) 2015-05-27
WO2012017323A2 (en) 2012-02-09
GB2497453B (en) 2017-07-12
GB2497453A (en) 2013-06-12
RU2535034C2 (ru) 2014-12-10
EA201300132A1 (ru) 2013-11-29
US20120294899A1 (en) 2012-11-22
WO2012017323A3 (en) 2012-04-12
UA112842C2 (uk) 2016-11-10
GB2497453B8 (en) 2018-01-31
RU2010133048A (ru) 2012-02-20
DE112011102638T5 (de) 2013-07-25

Similar Documents

Publication Publication Date Title
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
CO6460769A2 (es) Inhibidores de la replicación viral novedosos
PH12013501842A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
ECSP10010295A (es) Formulacion de anticuerpo
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
IN2012DN02805A (es)
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UY35210A (es) Inhibidores de autotaxina
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
ES2555557R1 (es) Fármaco y uso para preparar un medicamento destinado a la prevención de la infección del VIH y al tratamiento de enfermedades causadas por el VIH, incluido el SIDA
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20170828